[A22-53] Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V
Last updated 20.10.2022
Commission awarded on 02.05.2022 by the Federal Joint Committee (G-BA).
Adult patients with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection
- Patients who are eligible for cisplatin-containing therapy for adjuvant treatment: added benefit not proven
- Patients who are not eligible for cisplatin-containing therapy for adjuvant treatment: hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.